Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: A major clinical challenge

Clinical Microbiology and Infection

Volumn 19, Issue 2, 2013, Pages

  Navarro San Francisco, C ^a   Mora Rillo, M ^a   Romero Gomez M P ^a   Moreno Ramos, F ^a   Rico Nieto, A ^a   Ruiz Carrascoso, G ^a   Gomez Gil R ^a   Arribas Lopez J R ^a   Mingorance, J ^a   Pano Pardo J R ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

Author keywords

Bloodstream infection; Carbapenemase; OXA 48

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEMASE; CEFEPIME; CEFOTAXIME; CEFOTAXIME PLUS CLAVULANIC ACID; CEFOXITIN; CEFTAZIDIME; CEFTAZIDIME PLUS CLAVULANIC ACID; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; CATHETER INFECTION; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; DRUG EXPOSURE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENZYME SYNTHESIS; ESCHERICHIA COLI INFECTION; FEMALE; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IATROGENIC DISEASE; INVASIVE PROCEDURE; KLEBSIELLA PNEUMONIAE INFECTION; LENGTH OF STAY; MALE; MEDICAL RECORD REVIEW; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; OBSERVATIONAL STUDY; OXA 48 CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SURGICAL INFECTION; THERAPY DELAY; URINARY TRACT INFECTION;

ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE;

EID: 84873526138     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12091     Document Type: Article

References (29)

1. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67: 1597-1606.
2. Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53: 60-67.
3. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011; 17: 1135-1141.
4. Poirel L, Castanheira M, Carrër A et al. OXA-163, an OXA-48-related class D β-lactamase with extended activity toward expanded-spectrum cephalosporins. Antimicrob Agents Chemother 2011; 55: 2546-2551.
5. Carrër A, Poirel L, Yilmaz M et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob Agents Chemother 2010; 54: 1369-1373.
6. Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother 2008; 52: 2950-2954.
7. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 2004; 48: 15-22.
8. Pitart C, Solé M, Roca I, Fàbrega A, Vila J, Marco F. First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 beta-lactamase in Klebsiella pneumoniae in Spain. Antimicrob Agents Chemother 2011; 55: 4398-4401.
9. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother 2011; 55: 2420-2423.
10. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16: 128-140.
11. Friedman ND, Kaye KS, Stout JE et al. Health care-associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137: 791-797.
12. Charlson ME, Charlson RE, Peterson JC, Marinopoulos SS, Briggs WM, Hollenberg JP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol 2008; 61: 1234-1240.
13. McCabe WR, Jackson GG. Gram-negative bacteremia: I. Etiology and ecology. Arch Intern Med 1962; 110: 847.
14. Chow JW, Yu VL. Combination antibiotic therapy versus monotherapy for gram-negative bacteraemia: a commentary. Int J Antimicrob Agents 1999; 11: 7-12.
15. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
16. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55: 943-950.
17. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI M100-S22. CLSI, Wayne, PA, USA, 2012.
18. Aubert D, Naas T, Héritier C, Poirel L, Nordmann P. Functional characterization of IS1999, an IS4 family element involved in mobilization and expression of beta-lactam resistance genes. J Bacteriol 2006; 188: 6506-6514.
19. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20: 440-458.
20. Healy M, Huong J, Bittner T et al. Microbial DNA typing by automated repetitive-sequence-based PCR. J Clin Microbiol 2005; 43: 199-207.
21. Diancourt L, Passet V, Verhoef J, Grimont PAD, Brisse S. Multilocus sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 2005; 43: 4178-4182.
22. Pano-Pardo JR, Ruiz-Carrascoso G, Navarro San Francisco C et al. Infections caused by OXA-48-producing Klebsiella pneumoniae in a tertiary hospital in Spain in the setting of a prolonged, hospital-wide outbreak. J Antimicrob Chemother 2012; [Epub ahead of print].
23. Potron A, Kalpoe J, Poirel L, Nordmann P. European dissemination of a single OXA-48-producing Klebsiella pneumoniae clone. Clin Microbiol Infect 2011; 17: E24-E26.
24. Pfeifer Y, Schlatterer K, Engelmann E et al. Emergence of OXA-48-type carbapenemase-producing Enterobacteriaceae in German hospitals. Antimicrob Agents Chemother 2012; 56: 2125-2128.
25. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37: 415-419.
26. Mimoz O, Grégoire N, Poirel L, Marliat M, Couet W, Nordmann P. Broad-spectrum β-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48. Antimicrob Agents Chemother 2012; 56: 2759-2760.
27. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin Microbiol Infect 2012; 18: 439-448.
28. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob Agents Chemother 2009; 53: 1868-1873.
29. Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2012; 18: 1503-1507.